AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16436852
Drug: Levobupivacaine (0.25%)
RxNorm normalized name: levobupivacaine 0.25 MG/ML
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (0.25%) bolus and infusion (group II)
Trial: 16436852
Drug: Saline bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline bolus (30 ml) plus saline infusion (270 ml at 5 ml/h, placebo group)
Trial: 15123483
Drug: Enteral rehydration
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral rehydration therapy
Trial: 9017769
Drug: Furosemide products
RxNorm normalized name: furosemide Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide products (one intravenous and four oral tablet formulations)
Trial: 3674221
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (7 mg/kg)
Trial: 1101066
Drug: High titer
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titer globulin (3 ml, repeated at four months)
Trial: 1101066
Drug: Intermediate titer
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate titer globulin (3 ml, repeated at four months)
Trial: 1101066
Drug: Normal titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal titer globulin (3 ml, repeated at four months)
Trial: 26036793
Drug: Conventional CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CT scan (Group A): Tube voltage 120 kVp, automatic current modulation with a Noise Index of 12, ASIR 30%, injected with Iohexol (350 mgI/ml)
Trial: 26036793
Drug: Spectral CT
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectral CT Imaging (Group B): Tube current of 600 mA, injected with Iodixanol (270 mgI/ml)
Trial: 23322408
Drug: Chitosan-dextran (CD)
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan-dextran (CD) gel applied unilaterally
Trial: 23322408
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no gel applied on contralateral sides)
Trial: 21761711
Drug: Clarithromycin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS with nasal polyps
Trial: 21761711
Drug: Clarithromycin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS without nasal polyps
Trial: 17289155
Drug: Higher levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher levels of nicotine dependence and concurrent hazardous use of alcohol or cannabis
Trial: 15229205
Drug: Individualized GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized GnRH antagonist regimen (flexible regimen)
Trial: 15229205
Drug: Standard GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GnRH antagonist regimen (fixed regimen)
Trial: 9205816
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of rhIL-11 at 10-50 micrograms kg-1 for 1 or 3 hours
Trial: 9205816
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of rhIL-11 at 3-50 micrograms kg-1
Trial: 9205816
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of rhIL-11 at 3 micrograms kg-1 once daily for 7 days
Trial: 9205816
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of rhIL-11 at 50 micrograms kg-1
Trial: 9205816
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of rhIL-11
Trial: 8381643
Drug: Clotrimazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (200 mg/day)
Trial: 2957801
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg once daily for the first 2 days, then 20 mg once daily for 5 days
Trial: 18973893
Drug: Daily 100
RxNorm normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily 100 mg aspirin
Trial: 29475433
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of 24% sucrose
Trial: 29475433
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of 24% sucrose
Trial: 29475433
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml of 24% sucrose
Trial: 29475433
Drug: All sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All sucrose doses
Trial: 23707316
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol absorption (measured by cholestanol-to-cholesterol ratio, CR)
Trial: 23707316
Drug: Cholesterol absorption
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol absorption (CR)
Trial: 20712886
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine monotherapy (1250 mg/m2 twice daily)
Trial: 20712886
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and vinorelbine (dose level 2)
Trial: 16699663
Drug: Normal Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Tenon's capsule
Trial: 15298634
Drug: Lansoprazole orally
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube
Trial: 15298634
Drug: Intact lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Trial: 3541596
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 or 20 mg orally three times daily)
Trial: 20694775
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine group (CM)
Trial: 20694775
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (WM)
Trial: 18471409
Drug: Astragalous Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalous Injection
Trial: 8678496
Drug: Simultaneous combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous combination of TAM & MPA
Trial: 8678496
Drug: Alternating sequential
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating sequential combination of TAM plus MPA (TAM‐MPA)
Trial: 8678496
Drug: MPA as
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA as second-line therapy after TAM
Trial: 1765356
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg uid
Trial: 6357037
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (Control)
Trial: 30524749
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone used in conjunction with iNO
Trial: 27491224
Drug: Liuwei Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liuwei Dihuang Pill (LDP) and Ginkgo Leaf Tablet (GLT)
Trial: 27491224
Drug: Liuwei Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liuwei Dihuang Pill (placebo) and Ginkgo Leaf Tablet (placebo)
Trial: 16361624
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg orally once a day
Trial: 16361624
Drug: Gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 500 mg orally once a day
Trial: 10798055
Drug: Prednisolone (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (daily 60 mg/m2 for 4 weeks, then 45, 30, 20, 10, 5 mg/m2 on alternate days for 4 weeks)
Trial: 10798055
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone (HDMP) (30 mg/kg/d for 3 days, 20 mg/kg/d for 4 days, 10 mg/kg/d for 1 week)
Trial: 8576660
Drug: I.M. method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. method (Intramuscular)
Trial: 2127674
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nicergoline
Trial: 27509187
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 3000 IU/day
Trial: 24809921
Drug: Trimetazidine treatment
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine treatment group (TG)
Trial: 24809921
Drug: Trimetazidine treatment
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine treatment
Trial: 21968279
Drug: Adrenocorticotropic hormone
RxNorm normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropic hormone stimulation
Trial: 19648224
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Modafinil
Trial: 17504903
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 1000 mg im (first dose), followed by 500 mg im every 6 weeks
Trial: 17504903
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) plus oral levonorgestrel (LNG) 250 microg/d
Trial: 17504903
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment only
Trial: 9653685
Drug: Joint mobilization
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint mobilization and comprehensive treatment (hot packs, active range of motion, physiologic stretching, muscle strengthening, soft tissue mobilization, and patient education)
Trial: 9653685
Drug: Joint mobilization
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint mobilization and comprehensive treatment
Trial: 9653685
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment alone
Trial: 26522708
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks through week 24 and every 8 weeks through week 48.
Trial: 26522708
Drug: Grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grid laser at baseline and IAI every 8 weeks after 3 monthly doses from week 24 onward (laser/IAI group).
Trial: 26522708
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg.
Trial: 24029269
Drug: Nicotinamide 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide 500 mg twice/day
Trial: 18556747
Drug: Icodextrin-containing PD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icodextrin-containing PD solutions (Extraneal)
Trial: 18556747
Drug: Non-icodextrin-containing PD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-icodextrin-containing PD solutions
Trial: 16979005
Drug: Pharmacologic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic Therapy (PT) alone
Trial: 14551366
Drug: Low-dose spironolactone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spironolactone (25 mg three times/week)
Trial: 11256554
Drug: Pranlukast (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (450 mg/day)
Trial: 11256554
Drug: Bronchodilators and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day)
Trial: 11256554
Drug: Bronchodilators alone
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators alone
Trial: 8171288
Drug: Activated peroral
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated peroral charcoal (50 g 3 times a day for 8 days)
Trial: 3146125
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g single dose at the time of surgery)
Trial: 18585635
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy with maintenance protocol
Trial: 18585635
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy with maintenance treatment
Trial: 18585635
Drug: BCG maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG maintenance treatment
Trial: 18585635
Drug: SWOG protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SWOG protocol for BCG therapy
Trial: 18585635
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of BCG
Trial: 18585635
Drug: Individualized approach
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized approach to BCG therapy
Trial: 10999784
Drug: Metyrapone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (500 mg every 4 h)
Trial: 9081136
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) 60 micrograms, intravenous infusion, 5 days a week for 4 weeks, followed by twice a week for 4 weeks
Trial: 29231562
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of western medication
Trial: 24405492
Drug: Threshold suspend
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold suspend (TS) feature, insulin stopped for 2 hours once SG value of ≤70 mg/dL detected
Trial: 24405492
Drug: Control (basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (basal insulin delivery continued)
Trial: 19931156
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg as an intermittent bolus 3 times a day)
Trial: 19931156
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg as an intermittent bolus twice a day)
Trial: 15288222
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the vaginal vault
Trial: 15288222
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the cervix
Trial: 8689733
Drug: Geristore restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geristore restoration system after cavity cleaned with 10% NaOCl solution and 3% H2O2 solution (Group G)
Trial: 8689733
Drug: Geristore restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geristore restoration system after cavity applied with Mirage-Bond (Group MG)
Trial: 3803702
Drug: Esaprazole 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaprazole 900 mg
Trial: 3583500
Drug: Esaprazole 1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaprazole 1800 mg
Trial: 30825795
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine Patch
Trial: 21926186
Drug: subcutaneous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous placebo + methotrexate
Trial: 15343195
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin injection therapy
Trial: 11177203
Drug: Bicarbonate-rich mineral
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-rich mineral water (1715 mg bicarbonate/l)
Trial: 9051880
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 0.5 g daily for 2 years
Trial: 8378156
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (50 mg/kg)/promethazine (1 mg/kg)
Trial: 8378156
Drug: Meperidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (1 mg/kg)/promethazine (1 mg/kg)
Trial: 2878859
Drug: Azodisal sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azodisal sodium (1 g/day)
Trial: 2878859
Drug: Azodisal sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azodisal sodium (1 g/day vs 2 g/day)
Trial: 2878859
Drug: Azodisal sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azodisal sodium (2 g/day)
Trial: 2878859
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or sulphasalazine (2 g/day)
Trial: 24377219
Drug: Medication (M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (M group)
Trial: 14746859
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg, ondansetron 32 mg i.v., dexamethasone 12 mg on day 1, aprepitant 80 mg and dexamethasone 8 mg on days 2-3, dexamethasone 8 mg on day 4
Trial: 14746859
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ondansetron 32 mg i.v. and dexamethasone 20 mg on day 1, dexamethasone 8 mg b.i.d. on days 2-4)
Trial: 8510490
Drug: 12-month course
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month course of alfa interferon therapy
Trial: 3319536
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day GVG
Trial: 3319536
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day GVG
Trial: 23432812
Drug: PHiD‐CV co‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV co‐administered with DTPa‐HBV‐IPV/Hib
Trial: 17534460
Drug: Thiazide diuretics
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretics as initial therapy for adults without compelling indications for other agents.
Trial: 17534460
Drug: ACE inhibitors,
RxNorm normalized name: ACE INHIBITORS, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, long-acting CCBs, ARBs, or beta-blockers as first-line therapy for diastolic and/or systolic hypertension.
Trial: 17534460
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors recommended for nondiabetic chronic kidney disease patients.
Trial: 17534460
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy for selected high-risk patients with hypertension.
Trial: 11588128
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg daily)
Trial: 7987837
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min
Trial: 7987837
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min with SR-2508 at 5 g/m2 infused over 20 min